Early Breast Cancer clinical trials

Explore recruiting early breast cancer clinical trials.

Recruiting early breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Early Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Spain, Italy, Belgium, Austria, Portugal, Sweden +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer

Austria, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)

Poland, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation with metastatic nodes. Part of a platform of translational phase II trials based on molecular subtypes.

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

PREDIX HER2 - Neoadjuvant response-guided treatment of HER2 positive breast cancer. Part of a platform of translational phase II trials based on molecular subtypes

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study (COGNITION-GUIDE)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Early Breast Cancer trials by city

Early Breast Cancer in Toronto Early Breast Cancer in Vancouver Early Breast Cancer in Montreal Early Breast Cancer in Calgary Early Breast Cancer in Edmonton Early Breast Cancer in Ottawa Early Breast Cancer in Winnipeg Early Breast Cancer in Quebec City Early Breast Cancer in Hamilton Early Breast Cancer in Kitchener Early Breast Cancer in London Early Breast Cancer in Halifax Early Breast Cancer in New York Early Breast Cancer in Los Angeles Early Breast Cancer in Chicago Early Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease